Skip to main content
SpringerLink
Log in

Hepatozelluläres Karzinom – Screening und Surveillance

Hepatocellular carcinoma—screening and surveillance

  • Schwerpunkt
  • Published:
Die Gastroenterologie Aims and scope

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) als primärer Lebertumor ist der weltweit häufigste maligne Lebertumor mit deutlich steigender Inzidenz. Bei 80 % der Patienten mit einem HCC kann eine fortgeschrittene Leberfibrose oder -zirrhose gefunden werden. Die S3-Leitlinie empfiehlt die Prävention einer chronischen Lebererkrankung (z. B. durch Impfung gegen viralbedingte Hepatitiden), eine frühzeitige Behandlung der Grunderkrankung (z. B. mittels antiviraler Therapie) sowie die Teilnahme an einer HCC-Früherkennung bei entsprechenden Risikogruppen. So kann mithilfe von Screening- und Überwachungsprogrammen ein HCC im Frühstadium erkannt, kurativ therapiert und die Mortalität gesenkt werden.

Abstract

Hepatocellular carcinoma (HCC) as a primary liver tumor is the most common malignant liver tumor worldwide with a clearly increasing incidence. Advanced liver fibrosis or cirrhosis can be found in 80% of patients with HCC. The S3 guideline recommends prevention of chronic liver disease (e.g., by vaccination against viral hepatitis), early treatment of the underlying disease (e.g., by means of antiviral therapy), and participation in HCC early detection in risk groups. With the help of screening and monitoring programs, HCC can be detected in the early stages, curatively treated and mortality can be reduced.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Sung H, Jacques F, Siegel RL, Bray F et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71(3):209–249

    Article  Google Scholar 

  2. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2021/kid_2021_c22_leber.pdf;jsessionid=A52882D31BF2F6005379A4EC05DD16EB.internet112?__blob=publicationFile. Zugegriffen: 12. Juni 2022

  3. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma; European association for the Study of the liver; https://doi.org/10.1016/j.jhep.2018.03.019

  4. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C (2008) Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 48:137–145

    Article  PubMed  Google Scholar 

  5. S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome. Langversion 2.0 – Juni 2021 AWMF-Registernummer: 032 – 053OL

  6. Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687

    Article  PubMed  CAS  Google Scholar 

  7. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(5 Suppl 1):S35–S50

    Article  PubMed  Google Scholar 

  8. White DL, Kanwal F, El-Serag HB (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10:1342–1359

    Article  PubMed  PubMed Central  Google Scholar 

  9. Singal AG, Pillai A, Tiro J (2014) Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 11:e1001624

    Article  PubMed  PubMed Central  Google Scholar 

  10. Yang B, Zhang B, Xu Y et al (1997) Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 123:357–360

    Article  PubMed  CAS  Google Scholar 

  11. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422

    Article  PubMed  Google Scholar 

  12. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69:182–236. [PubMed: 29628281]

  13. Covey AM (2018) Hepatocellular carcinoma: updates to screening and diagnosis. J Natl Compr Cancer Netw 16(5S):663–665

    Article  Google Scholar 

  14. Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370

    Article  PubMed  Google Scholar 

  15. Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380

    Article  PubMed  Google Scholar 

  16. Kanwal F, Singal AG (2019) Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 157(1):54–64. https://doi.org/10.1053/j.gastro.2019.02.049

    Article  PubMed  Google Scholar 

  17. Sharma SA, Kowgier M, Hansen BE, Brouwer PW, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote JE, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ (2017) Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol. https://doi.org/10.1016/j.jhep.2017.07.033

    Article  PubMed  Google Scholar 

  18. Papatheodoridis G et al (2016) PAGE‑B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5‑year antiviral therapy. J Hepatol 64(4):800–806

    Article  PubMed  CAS  Google Scholar 

  19. Semmler G, Meyer EL, Kozbial K et al (2021) HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. https://doi.org/10.1016/j.jhep.2021.11.025

    Article  PubMed  Google Scholar 

  20. Younossi ZM (2019) Non-alcoholic fatty liver disease—A global public health perspective. J Hepatol 70:531–544

    Article  PubMed  Google Scholar 

  21. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431

    Article  PubMed  Google Scholar 

  22. Ertle J, Canbay A et al (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128(10):2436–2443. https://doi.org/10.1002/ijc.25797

    Article  PubMed  CAS  Google Scholar 

  23. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, APRICOT Clinical Investigators (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43(6):1317–1325. https://doi.org/10.1002/hep.21178

    Article  PubMed  CAS  Google Scholar 

  24. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG (2019) Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol 25:1550–1559

    Article  PubMed  PubMed Central  Google Scholar 

  25. Tzartzeva K, Obi J, Rich N et al (2018) Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154:1706

    Article  PubMed  CAS  Google Scholar 

  26. Pocha C, Dieperink E et al (2013) Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography—a randomised study. Aliment Pharmacol Ther 38:303–312

    Article  PubMed  CAS  Google Scholar 

  27. Marrero JA, Feng Z et al (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1):110–118. https://doi.org/10.1053/j.gastro.2009.04.005

    Article  PubMed  CAS  Google Scholar 

  28. Czauderna C et al (2021) High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterol J. https://doi.org/10.1177/2050640620972611

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zhang X, Wang T, Zhang KH, Chen SH, He YT, Wang YQ (2019) Simple clinical metrics enhance AFP to effectively identify cirrhotic patients with complicating hepatocellular carcinoma at various AFP levels. Front Oncol 9:1478

    Article  PubMed  Google Scholar 

  30. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34(4):570–575. https://doi.org/10.1016/s0168-8278(00)00053-2

    Article  PubMed  CAS  Google Scholar 

  31. França AV, Junior EJ, Lima BL, Martinelli AL, Carrilho FJ (2004) Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 37:1689–1705

    Article  PubMed  Google Scholar 

  32. Johnson PJ, Pirrie SJ, Satomura S et al (2014) The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 23(1):144–153. https://doi.org/10.1158/1055-9965.EPI-13-0870

    Article  PubMed  CAS  Google Scholar 

  33. Best J, Bechmann LP, Canbay A et al (2020) GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Gastroenterol Hepatol 18(3):728–735.e4. https://doi.org/10.1016/j.cgh.2019.11.012.Epub

    Article  CAS  Google Scholar 

  34. Yu JJ, Xiao W, Dong SL, Liang HF, Zhang ZW, Zhang BX et al (2018) Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer 18(1):835. https://doi.org/10.1186/s12885-018-4744-4

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ (2000) Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 6(9):3516–3521

    PubMed  CAS  Google Scholar 

  36. Huang Z, Hua D, Hu Y, Cheng Z, Zhou X, Xie Q et al (2012) Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. Pathol Oncol Res 18(2):271–276. https://doi.org/10.1007/s12253-011-9438-z

    Article  PubMed  CAS  Google Scholar 

  37. Ye Q, Xu X et al (2019) Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer 18:114

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik – Sektion Gastrointestinale Onkologie, Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, In der Schornau 23–25, 44892, Bochum, Deutschland

    Christina C. Köpping-Segerling & Michael Pohl

  2. Medizinische Klinik – Sektion Gastroenterologie und Hepatologie, Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, In der Schornau 23–25, 44892, Bochum, Deutschland

    Ali Canbay & Jan Best

  3. Medizinische Klinik, Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, In der Schornau 23–25, 44892, Bochum, Deutschland

    Ali Canbay

Authors
  1. Christina C. Köpping-Segerling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Pohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Canbay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan Best
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Canbay.

Ethics declarations

Interessenkonflikt

C.C. Köpping-Segerling, M. Pohl, A. Canbay und J. Best geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Julia Mayerle, München

Ali Canbay, Bochum

Michael Fried, Zürich

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Köpping-Segerling, C.C., Pohl, M., Canbay, A. et al. Hepatozelluläres Karzinom – Screening und Surveillance. Gastroenterologie 17, 387–392 (2022). https://doi.org/10.1007/s11377-022-00651-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-022-00651-6

Schlüsselwörter

Keywords

Search

Navigation